Evidence map›Paper›PMID 23131853›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2012

rAAV-mediated tumorigenesis: still unresolved after an AAV assault.

Paul N Valdmanis, Leszek Lisowski, Mark A Kay

Abstract readComment
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Review
  3. Gene therapy for the heart: encapsulated viruses to the rescue.Extracellular vesicles and circulating nucleic acids · 2024
    Article
  4. Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. A Changing World in Gene Therapy Research: Exciting Opportunities for Medical Advancement and Biosafety Challenges.Applied biosafety : journal of the American Biological Safety Association · 2021
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Progress and challenges of gene therapy for Pompe disease.Annals of translational medicine · 2019
    Review
  16. Emerging Issues in AAV-MediatedMolecular therapy. Methods & clinical development · 2018
    Review
  17. Article
  18. Article
  19. Short DNA Hairpins Compromise Recombinant Adeno-Associated Virus Genome Homogeneity.Molecular therapy : the journal of the American Society of Gene Therapy · 2017
    Article
  20. AAV Infection: Protection from Cancer.Human gene therapy · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Paul N ValdmanisDepartments of Pediatrics and Genetics, Stanford University, Stanford, California 94305, USA.
Leszek Lisowski
Mark A Kay

Funding

HEPATIC GENE TRANSFER FOR TREATMENT OF HEMOPHILIAS A &BR01HL064274 · NHLBI · STANFORD UNIVERSITY · PI Mark A Kay · 2000 to 2026
$13.6M
NHLBI NIH HHS R01 HL064274
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Mutagenesis, InsertionalVirus IntegrationAnimalsCarcinoma, HepatocellularDependovirusFemaleLiver Neoplasms, ExperimentalMale

Identifiers

PMID23131853
PMCPMC3498811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.